15:25:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-19 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning SUS 0.00 SEK
2024-05-16 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning SUS 0.00 SEK
2023-05-17 Årsstämma 2023
2023-05-16 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-13 Ordinarie utdelning SUS 0.00 SEK
2022-05-12 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-08-16 Extra Bolagsstämma 2021
2021-05-14 Ordinarie utdelning SUS 0.00 SEK
2021-05-12 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-25 Split SUS 1:5
2020-05-07 Ordinarie utdelning SUS 0.00 SEK
2020-05-06 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-07 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-07-17 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning SUS 0.00 SEK
2019-05-09 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-11-21 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-23 Ordinarie utdelning SUS 0.00 SEK
2018-05-22 Kvartalsrapport 2018-Q1
2018-05-22 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Surgical Science Sweden är verksamt inom medicinteknik. Bolaget utvecklar VR-simulatorer inom kirurgin. Simulatorerna består både hård- och mjukvara som används i träning och personlig utveckling hos kirurger. Hårdvaran simulerar diverse kirurgiska ingrepp, med främst användning inom titthålskirurgi samt endoskopi. Visionen är att stärka kompetensen inom kirurgin samt skapa förutsättningar för bättre behandlingar. Bolaget har sitt huvudkontor i Göteborg.
2021-05-11 08:30:00

FIRST QUARTER OF 2021 (JAN – MAR)

Net sales amounted to SEK 37.2 million (19.7), corresponding to an increase of 89 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 53 percent.

Operating profit amounted to SEK 2.2 million (loss 0.8). The outcome includes acquisition costs of SEK 6.0 million.

Net profit amounted to SEK 1.5 million (loss 0.7), corresponding to earnings per share of SEK 0.04 (loss 0.02).

Cash flow from operating activities was negative in the amount of SEK 8.9 million (5.3). As of March 31, 2021, cash and cash equivalents amounted to SEK 263.7 million (68.6).

On January 20, a conditional agreement was entered into to acquire all of the shares in Mimic Technologies Inc., which operates in the area of robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The initial valuation was USD 18 million (approximately SEK 150 million) on a cash and debt-free basis. In addition, a maximum USD 15.6 million (approximately SEK 130 million) may be paid as a deferred contingent consideration.

A directed share issue of approximately SEK 322 million was implemented, in which a number of new and existing Swedish and international institutional investors subscribed for shares. The transfer of ownership took place on January 27, once all of the terms of transfer had been met. Mimic was consolidated within Surgical Science as of the transfer date.

Gothenburg, Sweden, May 11, 2021
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.